GERN Geron Corp

Price (delayed)

$1.2

Market cap

$769.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$950.89M

?
Relative Growth: Rel. Growth: 91
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 44

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two ...

Highlights
The revenue has soared by 69% YoY and by 7% from the previous quarter
The company's gross profit has surged by 68% YoY and by 7% QoQ
The quick ratio has grown by 36% from the previous quarter but it has contracted by 29% YoY
Geron's equity has decreased by 15% YoY

Key stats

What are the main financial stats of GERN

GERN stock price

How has the Geron stock price performed over time
Intraday
3.45%
1 week
-4%
1 month
-23.57%
1 year
-22.08%
YTD
-9.09%
QTD
-19.46%

Financial performance

How have Geron's revenue and profit performed over time
Revenue
$196.12M
Gross profit
$190.88M
Operating income
-$51.72M
Net income
-$67.31M
Gross margin
97.3%
Net margin
-34.3%
The operating margin has soared by 77% year-on-year and by 29% since the previous quarter
GERN's net margin has surged by 71% year-on-year and by 24% since the previous quarter
The revenue has soared by 69% YoY and by 7% from the previous quarter
The company's gross profit has surged by 68% YoY and by 7% QoQ

Price vs fundamentals

How does GERN's price correlate with its fundamentals

Growth

What is Geron's growth rate over time

Valuation

What is Geron stock price valuation
P/E
N/A
P/B
3.35
P/S
4.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.85
Geron's EPS has increased by 48% YoY and by 15% from the previous quarter
The P/B is 38% below the 5-year quarterly average of 5.2 and 12% below the last 4 quarters average of 3.7
Geron's equity has decreased by 15% YoY
The P/S is 100% below the 5-year quarterly average of 1338.6 and 22% below the last 4 quarters average of 5.1
The revenue has soared by 69% YoY and by 7% from the previous quarter

Efficiency

How efficient is Geron business performance
Geron's ROS has soared by 82% YoY and by 34% from the previous quarter
Geron's ROIC has soared by 76% YoY and by 29% from the previous quarter
The ROA has soared by 55% YoY and by 18% from the previous quarter
GERN's ROE is up by 42% year-on-year and by 16% since the previous quarter

Dividends

What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GERN.

Financial health

How did Geron financials performed over time
Geron's total assets is 75% higher than its total liabilities
GERN's current ratio is up by 45% since the previous quarter but it is down by 14% year-on-year
The quick ratio has grown by 36% from the previous quarter but it has contracted by 29% YoY
GERN's debt is 10% greater than its equity
GERN's debt to equity is up by 20% YoY
Geron's equity has decreased by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.